[1] Nurtjahja-Tjendraputra E, Fu D, Phang JM, et al. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression[J]. Blood, 2007, 109(9): 4045-4054.
[2] Krishnan K, Prathiba K, Jayaprakash V, et al. Synthesis and ribonucleotide reductase inhibitory activity of thiosemicarbazones[J]. Bioorg Med Chem Lett, 2008, 18(23): 6248-6250.
[3] Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal[J]. Mutat Res, 2003, 533(12): 153-171.
[4] Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation[J]. Blood, 2004, 104(9): 2967-2975.
[5] Rao VA, Zhang J, Klein SR, et al. The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats[J]. Cancer Chemother Pharmacol, 2011, 68(5): 1125-1134.
[6] Gao J, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression[J]. Blood, 2001, 98(3): 842-850.
[7] Lui GY, Obeidy P, Ford SJ, et al. The iron chelator, deferasirox, as a novel strategy for cancer Treatment: oral activity against human lung tumor xenografts and molecular mechanism of action[J]. Mol Pharmacol, 2013,83(1):179-190.
[8] Snyder AM, Wang X, Patton SM, et al. Mitochondrial ferritin in the substantia nigra in restless legs syndrome[J]. J Neuropathol Exp Neurol, 2009, 68(11): 1193-1199.
[9] Shi ZH, Nie G, Duan XL, et al. Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamineinduced dopaminergic cell damage: implication for neuroprotection in Parkinson’s disease[J]. Antioxid Redox Signal, 2010, 13(6): 783-796.
[10]Wu WS, Zhao YS, Shi ZH, et al. Mitochondrial ferritin attenuates beta-amyloid-induced neurotoxicity: reduction in oxidative damage through the Erk/P38 mitogen-activated protein kinase pathways[J]. Antioxid Redox Signal, 2013,18(2):158-169.
[11]Santambrogio P, Biasiotto G, Sanvito F, et al. Mitochondrial ferritin expression in adult mouse tissues[J]. J Histochem Cytochem, 2007, 55(11): 1129-1137.
[12] Fukuchi K, Tomoyasu S, Watanabe H, et al. Iron deprivation results in an increase in p53 expression[J]. Biol Chem Hoppe Seyler, 1995, 376(10): 627-630.
[13] Drysdale J, Arosio P, Invernizzi R, et al. Mitochondrial ferritin: a new player in iron metabolism[J]. Blood Cells Mol Dis, 2002, 29(3): 376-383.
[14]Noulsri E, Richardson DR, Lerdwana S, et al. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells[J]. Am J Hematol, 2009, 84(3): 170-176.
[15]Wajapeyee N, Somasundaram K. Cell cycle arrest and apoptosis induction by activator protein 2alpha (AP-2alpha) and the role of p53 and p21WAF1/CIP1 in AP-2alpha-mediated growth inhibition[J]. J Biol Chem, 2003, 278(52): 52093-52101. |